Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings or view top-rated stocks.

9 brokerages have issued 1 year price targets for Teva Pharmaceutical Industries' shares. Their TEVA share price forecasts range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.78 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price.
View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts.

Teva Pharmaceutical Industries' stock was trading at $9.12 at the start of the year. Since then, TEVA shares have decreased by 1.9% and is now trading at $8.95.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our TEVA earnings forecast.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued its quarterly earnings results on Wednesday, February, 8th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.04. The firm earned $3.88 billion during the quarter, compared to analysts' expectations of $3.90 billion. Teva Pharmaceutical Industries had a negative net margin of 15.76% and a positive trailing twelve-month return on equity of 28.06%.

ETFs with the largest weight of Teva Pharmaceutical Industries (NYSE:TEVA) stock in their portfolio include iShares MSCI Israel ETF (EIS), VanEck Israel ETF (ISRA), VanEck Pharmaceutical ETF (PPH), ARK Israel Innovative Technology ETF (IZRL), iShares MSCI Intl Value Factor ETF (IVLU), Invesco RAFI Strategic Developed ex-US ETF (ISDX) and Goldman Sachs ActiveBeta International Equity ETF (GSIE) and

Teva Pharmaceutical Industries issued an update on its FY23 earnings guidance on Wednesday, February, 8th. The company provided earnings per share guidance of $2.25-2.55 for the period, compared to the consensus earnings per share estimate of $2.52. The company issued revenue guidance of $14.8-15.4 billion, compared to the consensus revenue estimate of $15.19 billion.

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Phoenix Holdings Ltd. (2.00%), Migdal Insurance & Financial Holdings Ltd. (1.94%), Clal Insurance Enterprises Holdings Ltd (1.66%), Abrams Capital Management L.P. (1.43%), Harel Insurance Investments & Financial Services Ltd. (1.36%) and Exor Capital LLP (1.35%). Insiders that own company stock include David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends.

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TEVA stock can currently be purchased for approximately $8.95.

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $9.94 billion and generates $14.93 billion in revenue each year. The company earns $-2,353,000,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis.

The company employs 36,826 workers across the globe.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.